A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Keywords

ClinConnect Summary

HAART is a potent suppressor of plasma and lymph node HIV RNA. However, studies suggest that HAART cannot significantly diminish reservoirs of chronically HIV-infected cells. Strategies designed to eradicate all HIV infection should seek to actively target these reservoirs. CTX administration has been shown to eliminate a large number of lymphoid tissue T cells and macrophages, appearing to actively target chronically HIV-infected cells. As lymphoid organs are repopulated following initial depletion with CTX, HAART may protect repopulating cells from becoming HIV-infected, resulting in a ne...

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• You may be eligible for this study if you:
• • Are HIV-positive.
• • Have a CD4 count above 300 cells/mm3 within 30 days of study entry.
• • Have an HIV viral load between 10,000 and 200,000 copies/ml.
• • Are between the ages of 18 and 50.
• • Agree to practice abstinence or to use a barrier method of birth control during the study (such as condoms).
• • Exclusion Criteria
• You may not be eligible for this study if you:
• • Have had cancer requiring chemotherapy or radiotherapy or certain nervous system diseases.
• • Are sensitive to E. coli-derived proteins.
• • Have an active AIDS-defining illness.
• • Require certain medications.
• • Are pregnant or breast-feeding.